Abstract Library

#4050 PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,

#3876 Comprehensive characterization of the NET methylome

Introduction: The methylome holds great promise for biomarker discovery in neuroendocrine tumors (NETs), as changes in DNA methylation allow differentiation into relevant subgroups and reveal tissue of origin. However, a comprehensive characterization of the NET methylome is lacking, hampering biological insight and meaningful biomarker selection.

Conference:

Presenting Author: Mariën L

Authors: Mariën L, Ibrahim J, Cremers T, Lybaert W, Prenen H,

Keywords: neuroendocrine tumor, DNA methylation, pathway analysis, biomarker selection,

#3422 Longitudinal copy number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis and follow-up

Introduction: Research on liquid biopsies in neuroendocrine neoplasms (NENs) remains limited, despite the urgent need for new, preferably blood-based, biomarkers. Copy number alterations (CNAs) represent an important type of molecular alteration in NENs and are detectable in cell-free DNA (cfDNA).

Conference:

Presenting Author:

Authors: Mariën L, Boons G, Vandamme T, Lybaert W, Roeyen G,

Keywords: neuroendocrine neoplasm, liquid biopsies, circulating tumor DNA, biomarker, copy number alterations,

#3202 Plasma cell-free DNA from metastatic gastroenteropancreatic neuroendocrine neoplasms contains tumor-associated copy number alterations

Introduction: Recently, tumor-derived molecular alterations were detected in cell-free DNA (cfDNA) from gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) patients. In-depth evaluation of the biomarker potential of cfDNA is warranted, as better blood-based biomarkers are needed for GEP-NENs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Boons G, Vandamme T, Lybaert W, Roeyen G, Rondou T,

Keywords: cell-free DNA, shallow whole-genome sequencing, gastroenteropancreatic neuroendocrine neoplasm, biomarker,

#2079 Excellent Survival Outcomes for NET Patients Treated within NETwerk, a Collaborative ENETS Center of Excellence

Introduction: Since 2016, patients with neuroendocrine tumors (NETs) of 9 hospitals in Belgium, are jointly discussed during multidisciplinary tumor boards (NET MDT) within NETwerk, a ENETS Center of Excellence.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Maurissen I, Lybaert W, Simoens M, Abrams P,

Keywords: Neuroendocrine tumors, Care networking,